Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15188MR)

This product GTTS-WQ15188MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15188MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2149MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ2856MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ259MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ9711MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ15510MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ12645MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ10023MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ8433MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW